Literature DB >> 3220007

Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers.

B Hampel1, H Lode, G Bruckner, P Koeppe.   

Abstract

In this study, the pharmacokinetic parameters of 2 different beta-lactamase inhibitors (sulbactam and clavulanic acid) in combination with 2 different aminobenzylpenicillins (ampicillin and amoxycillin) were compared. The study involved 10 healthy volunteers who received sulbactam 250 mg plus ampicillin 500 mg intravenously, clavulanic acid 100 mg plus amoxycillin 500 mg intravenously, sultamicillin equivalent to sulbactam 294 mg plus ampicillin 440 mg orally, and clavulanic acid 125 mg plus amoxycillin 500 mg orally in a crossover, randomised trial. Serum and urine concentrations of ampicillin, amoxycillin and clavulanic acid were assayed by agar diffusion test, and the concentrations of sulbactam by gas chromatography with mass spectrometry. Pharmacokinetic parameters were calculated according to open 1- and 2-compartment models. Test results showed that the addition of sulbactam significantly increases the bioavailability of oral ampicillin when the 2 drugs are administered in the form of the prodrug sultamicillin. Also, sulbactam does not interfere with the kinetics of intravenous ampicillin but increases the absorption of oral ampicillin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3220007     DOI: 10.2165/00003495-198800357-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  10 in total

1.  The parenteral kinetics of ampicillin/sulbactam in man.

Authors:  G Foulds; A K Knirsch; J P Stankewich; D R Weidler
Journal:  Int J Clin Pharmacol Res       Date:  1985

2.  A three-way crossover study to compare the pharmacokinetics and acceptability of sultamicillin at two dose levels with that of ampicillin.

Authors:  S Hartley; R Wise
Journal:  J Antimicrob Chemother       Date:  1982-07       Impact factor: 5.790

3.  Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration.

Authors:  R M Brown; R Wise; J M Andrews; J Hancox
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

4.  Pharmacokinetics of sulbactam and ampicillin following oral administration of sultamicillin with probenecid.

Authors:  A M Emmerson; D A Cox; L J Lees
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

5.  Pharmacokinetic studies of amoxicillin, potassium clavulanate and their combination.

Authors:  G Witkowski; H Lode; G Höffken; P Koeppe
Journal:  Eur J Clin Microbiol       Date:  1982-08       Impact factor: 3.267

6.  A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor.

Authors:  N Aswapokee; H C Neu
Journal:  J Antibiot (Tokyo)       Date:  1978-12       Impact factor: 2.649

7.  Pharmacokinetics of sultamicillin in mice, rats, and dogs.

Authors:  A R English; D Girard; S L Haskell
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

8.  Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin.

Authors:  T Bergan
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

9.  Pharmacokinetics of sulbactam in humans.

Authors:  G Foulds; J P Stankewich; D C Marshall; M M O'Brien; S L Hayes; D J Weidler; F G McMahon
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

10.  Pharmacokinetics and bioavailability of sultamicillin estimated by high performance liquid chromatography.

Authors:  H J ROgers; I D Bradbrook; P J Morrison; R G Spector; D A Cox; L J Lees
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

  10 in total
  6 in total

1.  Neutralization of antimicrobial substances in new BacT/Alert FA and FN Plus blood culture bottles.

Authors:  Dieter Mitteregger; Wolfgang Barousch; Marion Nehr; Michael Kundi; Markus Zeitlinger; Athanasios Makristathis; Alexander M Hirschl
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.

Authors:  M K Lacy; W Lu; X Xu; P R Tessier; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

4.  Development and validation of limited-sampling strategies for predicting amoxicillin pharmacokinetic and pharmacodynamic parameters.

Authors:  G Suarez-Kurtz; F M Ribeiro; F L Vicente; C J Struchiner
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 5.  Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H A Friedel; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

6.  In vitro Combined Inhibitory Activities of β-Lactam Antibiotics and Clavulanic Acid Against bla KPC-2-Positive Klebsiella pneumoniae.

Authors:  Mingjia Peng; Renru Han; Yan Guo; Yonggui Zheng; Feifei Yang; Xiaogang Xu; Fupin Hu
Journal:  Infect Drug Resist       Date:  2021-02-02       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.